Opinion

Video

Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life

Author(s):

Jorge E. Cortes, MD,Joannie Clements

A panel of experts on chronic myeloid leukemia discuss common patient concerns, adverse effect considerations, and best practices for setting clear expectations.

This program was made possible with support from Novartis Pharmaceuticals.

Video content above is prompted by the following questions:

  • What are some of the most common concerns or questions newly diagnosed CML patients may have about their initial treatment plan?
  • What are some common adverse effects or tolerability challenges patients may experience with their initial treatment plan?
  • What is your best practice to set clear expectations with your patients on what they may experience along their CML journey?
Related Videos
Image of a woman with brown wavy hair, wearing a navy blue top.
A panel of 3 experts on CML
Related Content
Site Logo
June 2nd 2023

Georgia Cancer Center installs sunscreen dispensers across Augusta University campuses

What Is CAR-T Cell Therapy, and What Can Patients With Cancer Expect?
September 16th 2022

What Is CAR-T Cell Therapy, and What Can Patients With Cancer Expect?

Brielle Benyon
Over the past five years, CAR-T cell therapy has improved outcomes for many patients with blood cancer. Here’s what patients need to know about the immune-based treatment.
The 'Flipside' of Tumor Lysis Syndrome Shows Efficacy in Leukemia, Lymphoma
August 11th 2022

The 'Flipside' of Tumor Lysis Syndrome Shows Efficacy in Leukemia, Lymphoma

Andy Polhamus
Although tumor lysis syndrome may be dangerous and fatal if not treated early, experts note that it is a sign of successful treatment in patients with leukemia and lymphoma.
FDA OKs Continued Enrollment in Ongoing Blood Cancer Clinical Trials After Gilead Addresses Safety Concerns
April 15th 2022

FDA OKs Continued Enrollment in Ongoing Blood Cancer Clinical Trials After Gilead Addresses Safety Concerns

Brielle Benyon
Earlier in the year, clinical trials assessing magrolimab for myelodysplastic syndrome and acute myeloid leukemia were put on a partial clinical hold, but now the FDA said that they can start enrolling patients again.
New Treatments Lend a Positive Outlook to Patients With GVHD
February 28th 2022

New Treatments Lend a Positive Outlook to Patients With GVHD

Brielle Benyon
There are now more drugs than ever to treat and prevent graft-versus-host disease in patients with blood cancer who receive a stem cell transplant.
Trial Initiated to Study Protein-Inhibiting Treatment Option for Patients With Acute Leukemia
February 17th 2022

Trial Initiated to Study Protein-Inhibiting Treatment Option for Patients With Acute Leukemia

Jamie Cesanek
A trial to examine BMF-219 in patients with relapsed or refractory acute leukemias has begun recruiting patients across multiple U.S. states.